Silver Book Fact

Antihypertensive treatment has generated a benefit-to-cost ratio of at least 6:1 (6:1 in women and 10:1 in men).

Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Antihypertensive treatment has generated a benefit-to-cost ratio of at least 6:1 (6:1 in women and 10:1 in men).  
  • Because of the advent of imaging and noninvasive testing, Americans who are asymptomatic are being diagnosed with established cardiovascular disease.  
  • Cardiovascular disease death rates
    Cardiovascular disease accounts for nearly 801,000 deaths in the US, or about 1 of every 3 deaths in the US.  
  • The rise in beta-blocker treatment rates (34% since 1996) is proof that sustained attention and effective initiatives saves lives and improves quality of life.  
  • About 1/2 of the decrease in recent deaths in cardiovascular disease can be attributed to medical treatment.